Therapeutic Indications

Afatinib is indicated for:

Non-small cell lung cancer (NSCLC) with activating EGFR mutation

Irrespective of gender only Adults (18 years old or older)

Afatinib as monotherapy is indicated for the treatment of epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 40-50 mg once daily

Non-small cell lung cancer (NSCLC) of squamous histology

Irrespective of gender only Adults (18 years old or older)

Afatinib as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 40-50 mg once daily

Contraindications

Active ingredient Afatinib is contraindicated in the following cases: